Amyotrophic Lateral Sclerosis Treatment Market
Amyotrophic Lateral Sclerosis Treatment Market Size, Share & Trends Analysis Report by Drug Type (Disease-Modifying Therapies, Symptomatic Treatments, Combination Therapies), by Treatment Type (Pharmacological Treatment, Cell-Based Therapy, Gene Therapy, Supportive & Palliative Care, Assistive Respiratory Therapy), by End User (Hospitals, Neurology Clinics, Ambulatory Care Centers, Home Care Settings, Research & Academic Institutes), and Forecast Period (2026–2035)
Industry Overview
Amyotrophic Lateral Sclerosis treatment market was valued at $1.5 billion in 2025 and is projected to reach $3.5 billion by 2035, growing at a CAGR of 8.9% from 2026 to 2035. Market growth is being driven by the increasing prevalence of neurodegenerative disorders, rising orphan-drug development initiatives, and growing investments in precision neurology therapies. ALS continues to represent a critical unmet medical need due to its progressive and fatal nature, encouraging pharmaceutical companies to accelerate innovation in disease-modifying treatments. Manufacturers are increasingly focusing on antisense oligonucleotide therapies, neuroprotective drugs, stem-cell research, and gene-targeted medicines to improve survival rates and patient outcomes. In addition, supportive regulatory frameworks, orphan-drug incentives, and fast-track approval pathways are further promoting research and commercialization activities across the global ALS treatment landscape.
In April 2025, NeuroSense Therapeutics announced transformative Phase 2b microRNA data demonstrating the potential of PrimeC as a disease-modifying therapy for ALS. The study showed promising biomarker results associated with slowing disease progression and improving therapeutic response among ALS patients, further strengthening the company’s precision neurology strategy. In May 2024, Biogen received European Commission approval for QALSODY (tofersen) for the treatment of adults with SOD1-associated ALS. The approval marked one of the first gene-targeted therapies authorized in Europe for a genetic form of ALS and significantly strengthened the company’s rare neurological disease portfolio. The development is expected to improve patient access to advanced precision medicine therapies across the European ALS treatment market.
Market Dynamics
Precision ALS Therapies Drive Market Leadership
Disease-modifying therapies lead the Amyotrophic Lateral Sclerosis treatment market due to increasing demand for therapies that slow disease progression and improve long-term patient outcomes. Growing commercialization of edaravone-based drugs and antisense oligonucleotide therapies is significantly supporting segment expansion. Pharmaceutical companies are actively investing in biomarker-driven medicines and genetically targeted neurological treatments to enhance therapeutic effectiveness. Rising focus on precision medicine and orphan-drug innovation continues to strengthen the dominance of disease-modifying ALS therapies globally.
Gene Therapies Drive Innovation in the Amyotrophic Lateral Sclerosis Treatment Market
Gene therapy is emerging as the fastest-growing segment in the Amyotrophic Lateral Sclerosis treatment market due to increasing research into genetically linked ALS mutations and precision medicine approaches. Growing investment in antisense oligonucleotide therapies, RNA-targeting technologies, and orphan-drug development is accelerating innovation across neurodegenerative disease treatment. According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), more than 12,700 medicines were in clinical development globally in 2024, including therapies targeting rare neurological disorders. Rising pharmaceutical R&D investments and expansion of cell and gene therapies are expected to further strengthen growth opportunities in the ALS treatment market.
Market Segmentation
- Based on drug type, the market is segmented into disease-modifying therapies, symptomatic treatments, and combination therapies.
- Based on treatment type, the market is segmented into pharmacological treatment, cell-based therapy, gene therapy, supportive & palliative care, and assistive respiratory therapy.
- Based on end user, the market is segmented into hospitals, neurology clinics, ambulatory care centers, home care settings, and research & academic institutes.
Advanced Pharmacological Therapies Strengthen Growth in the ALS Treatment Market
Pharmacological treatment continues to dominate the Amyotrophic Lateral Sclerosis Treatment Market due to the widespread clinical adoption of approved therapies such as riluzole and edaravone. Hospitals and neurology clinics remain key treatment centers owing to the need for specialized neurological monitoring and long-term patient management. Increasing regulatory approvals for neuroprotective and disease-modifying drugs are further supporting market expansion. In March 2026, IQVIA launched IQVIA.ai, a unified agentic AI platform powered by NVIDIA to enhance clinical research, optimize pharmaceutical workflows, and accelerate commercialization strategies for advanced ALS pharmacological therapies.
Regional Outlook
The global Amyotrophic Lateral Sclerosis Treatment Market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America is the Leading Region in the Market
North America leads the global Amyotrophic Lateral Sclerosis treatment market owing to strong orphan-drug commercialization, advanced neurological healthcare infrastructure, and rising adoption of precision medicine therapies. The region continues to benefit from robust regulatory support from the U.S. FDA along with increasing investments in rare disease research and development activities. In January 2026, Neuro Sense Therapeutics completed the commercial manufacturing scale-up for PrimeC to support a potential Canadian market launch. This development is expected to strengthen the company’s commercialization capabilities and improve accessibility to advanced ALS therapies across North America.
Market Players Outlook
The major companies operating in the global Amyotrophic Lateral Sclerosis treatment market include Roche, Novartis, Sanofi, Takeda Pharmaceutical Company, and Regeneron Pharmaceuticals, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative treatment development to maintain their market positioning.
Recent Development
- In April 2026, La Jolla Labs announced that the first patient had been treated with GBFsen, a custom antisense oligonucleotide therapy developed for familial ALS associated with TDP-43 mutation. The development highlights increasing advancement in precision medicine and personalized gene-targeted therapies for rare neurodegenerative disorders. The milestone is expected to support innovation in next-generation ALS treatment approaches and expand therapeutic possibilities for genetically linked ALS patients.
- In March 2025, BrainStorm Cell Therapeutics announced its full-year 2024 financial results and provided a corporate update highlighting continued advancement of NurOwn for ALS treatment. The company emphasized ongoing regulatory engagement, clinical development activities, and strategic initiatives to support commercialization of its cell-based ALS therapy. The update reflects increasing industry focus on advanced regenerative and neuroprotective treatment approaches for ALS management.
- In December 2024, NeuroSense Therapeutics entered into a binding term sheet to advance the development and commercialization of PrimeC for ALS treatment. The agreement is expected to strengthen the company’s clinical development and market expansion strategy for its combination therapy targeting disease progression in ALS patients. The partnership supports broader commercialization efforts and reinforces ongoing innovation in neurodegenerative disease therapeutics.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global amyotrophic lateral sclerosis treatment market.
- Based on the availability of data, information related to new treatments and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Amyotrophic Lateral Sclerosis Treatment Market Sales Analysis – Drug Type | Treatment Type | End-User ($ Million)
- Amyotrophic Lateral Sclerosis Treatment Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach Analytics
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Amyotrophic Lateral Sclerosis Treatment Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers of Amyotrophic Lateral Sclerosis Treatment Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Amyotrophic Lateral Sclerosis Treatment Market: Impact Analysis
- Market Opportunities
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Amyotrophic Lateral Sclerosis Treatment Market Revenue and Share by Manufacturers
- Amyotrophic Lateral Sclerosis Treatment Type Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Roche
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sanofi
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Takeda Pharmaceutical Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Regeneron Pharmaceuticals
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Roche
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Amyotrophic Lateral Sclerosis Treatment Market Sales Analysis Drug Type ($ Million)
- Disease-Modifying Therapies
- Symptomatic Treatments
- Combination Therapies
- Amyotrophic Lateral Sclerosis Treatment Market Sales Analysis Treatment Type ($ Million)
- Pharmacological Treatment
- Cell-Based Therapy
- Gene Therapy
- Supportive & Palliative Care
- Assistive Respiratory Therapy
- Amyotrophic Lateral Sclerosis Treatment Market Sales Analysis End-User ($ Million)
- Hospitals
- Neurology Clinics
- Ambulatory Care Centers
- Home Care Settings
- Research & Academic Institutes
- Regional Analysis
- North American Amyotrophic Lateral Sclerosis Treatment Market Sales Analysis – Drug Type | Treatment Type | End-User| Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Amyotrophic Lateral Sclerosis Treatment Market Sales Analysis – Drug Type | Treatment Type | End-User| Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market Sales Analysis – Drug Type | Treatment Type | End-User| Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the Amyotrophic Lateral Sclerosis Treatment Market Sales Analysis – Drug Type | Treatment Type | End-User| Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Alexion Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amylyx Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Anavex Life Sciences
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Apellis Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aquestive Therapeutics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ascendis Pharma
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biogen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BrainStorm Cell Therapeutics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Calico Life Sciences
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Clene Nanomedicine
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cytokinetics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Denali Therapeutics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ionis Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- ITF Pharma
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mitsubishi Tanabe Pharma Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Neuraltus Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- NeuroSense Therapeutics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Orphazyme
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- QurAlis Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Regeneron Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Roche
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategiess
- Wave Life Sciences
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Alexion Pharmaceuticals
1. Global Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Drug Type, 2025-2035 ($ Million)
2. Global Disease-Modifying Therapies Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
3. Global Symptomatic Treatments Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
4. Global Combination Therapies Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
5. Global Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Treatment Type, 2025-2035 ($ Million)
6. Global Pharmacological Treatment Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
7. Global Cell-Based Therapy Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
8. Global Gene Therapy Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
9. Global Supportive & Palliative Care Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
10. Global Assistive Respiratory Therapy Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
11. Global Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By End-User, 2025-2035 ($ Million)
12. Global Amyotrophic Lateral Sclerosis Treatment For Hospitals Market Research and Analysis By Region, 2025-2035 ($ Million)
13. Global Amyotrophic Lateral Sclerosis Treatment For Neurology Clinics Market Research and Analysis By Region, 2025-2035 ($ Million)
14. Global Amyotrophic Lateral Sclerosis Treatment For Ambulatory Care Centers Market Research and Analysis By Region, 2025-2035 ($ Million)
15. Global Amyotrophic Lateral Sclerosis Treatment For Home Care Settings Market Research and Analysis By Region, 2025-2035 ($ Million)
16. Global Amyotrophic Lateral Sclerosis Treatment For Research & Academic Institutes Market Research and Analysis By Region, 2025-2035 ($ Million)
17. Global Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
18. North American Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
19. North American Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Drug Type, 2025-2035 ($ Million)
20. North American Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Treatment Type, 2025-2035 ($ Million)
21. North American Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By End-User, 2025-2035 ($ Million)
22. European Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
23. European Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Drug Type, 2025-2035 ($ Million)
24. European Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Treatment Type, 2025-2035 ($ Million)
25. European Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By End-User, 2025-2035 ($ Million)
26. Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
27. Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Drug Type, 2025-2035 ($ Million)
28. Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Treatment Type, 2025-2035 ($ Million)
29. Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By End-User, 2025-2035 ($ Million)
30. Rest of the World Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
31. Rest of the World Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Drug Type, 2025-2035 ($ Million)
32. Rest of the World Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By Treatment Type, 2025-2035 ($ Million)
33. Rest of the World Amyotrophic Lateral Sclerosis Treatment Market Research and Analysis By End-User, 2025-2035 ($ Million)
1. Global Amyotrophic Lateral Sclerosis Treatment Market Share By Drug Type, 2025 Vs 2035 ($ Million)
2. Global Disease-Modifying Therapies Amyotrophic Lateral Sclerosis Treatment Market Share By Region, 2025 Vs 2035 ($ Million)
3. Global Symptomatic Treatments Amyotrophic Lateral Sclerosis Treatment Market Share By Region, 2025 Vs 2035 ($ Million)
4. Global Combination Therapies Amyotrophic Lateral Sclerosis Treatment Market Share By Region, 2025 Vs 2035 ($ Million)
5. Global Amyotrophic Lateral Sclerosis Treatment Market Share By Treatment Type, 2025 Vs 2035 ($ Million)
6. Global Pharmacological Treatment Amyotrophic Lateral Sclerosis Treatment Market Share By Region, 2025 Vs 2035 ($ Million)
7. Global Cell-Based Therapy Amyotrophic Lateral Sclerosis Treatment Market Share By Region, 2025 Vs 2035 ($ Million)
8. Global Gene Therapy Amyotrophic Lateral Sclerosis Treatment Market Share By Region, 2025 Vs 2035 ($ Million)
9. Global Supportive & Palliative Care Amyotrophic Lateral Sclerosis Treatment Market Share By Region, 2025 Vs 2035 ($ Million)
10. Global Assistive Respiratory Therapy Amyotrophic Lateral Sclerosis Treatment Market Share By Region, 2025 Vs 2035 ($ Million)
11. Global Amyotrophic Lateral Sclerosis Treatment Market Share By End-User, 2025 Vs 2035 ($ Million)
12. Global Amyotrophic Lateral Sclerosis Treatment For Hospitals Market Share By Region, 2025 Vs 2035 ($ Million)
13. Global Amyotrophic Lateral Sclerosis Treatment For Neurology Clinics Market Share By Region, 2025 Vs 2035 ($ Million)
14. Global Amyotrophic Lateral Sclerosis Treatment For Ambulatory Care Centers Market Share By Region, 2025 Vs 2035 ($ Million)
15. Global Amyotrophic Lateral Sclerosis Treatment For Home Care Settings Market Share By Region, 2025 Vs 2035 ($ Million)
16. Global Amyotrophic Lateral Sclerosis Treatment For Research & Academic Institutes Market Share By Region, 2025 Vs 2035 ($ Million)
17. US Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
18. Canada Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
19. UK Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
20. France Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
21. Germany Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
22. Italy Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
23. Spain Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
24. Russia Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
25. Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
26. India Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
27. China Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
28. Japan Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
29. South Korea Amyotrophic Lateral Sclerosis Treatment, 2025-2035 ($ Million)
30. Australia and New Zealand Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
31. ASEAN Economies Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
32. Rest of Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
33. Latin America Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
34. Middle East and Africa Amyotrophic Lateral Sclerosis Treatment Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
